Janetzki S - Search Results

1

Measurement of cytokine release at the single cell level using the ELISPOT assay.

Cox JH, Ferrari G, Janetzki S. Cox JH, et al. Among authors: janetzki s. Methods. 2006 Apr;38(4):274-82. doi: 10.1016/j.ymeth.2005.11.006. Methods. 2006. PMID: 16473524

2

A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays.

Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, Ferrari G, Birx DL, Cox JH. Currier JR, et al. Among authors: janetzki s. J Immunol Methods. 2002 Feb 1;260(1-2):157-72. doi: 10.1016/s0022-1759(01)00535-x. J Immunol Methods. 2002. PMID: 11792386

3

Standardization and validation issues of the ELISPOT assay.

Janetzki S, Cox JH, Oden N, Ferrari G. Janetzki S, et al. Methods Mol Biol. 2005;302:51-86. doi: 10.1385/1-59259-903-6:051. Methods Mol Biol. 2005. PMID: 15937345

4

Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.

Janetzki S, Price L, Britten CM, van der Burg SH, Caterini J, Currier JR, Ferrari G, Gouttefangeas C, Hayes P, Kaempgen E, Lennerz V, Nihlmark K, Souza V, Hoos A. Janetzki S, et al. Cancer Immunol Immunother. 2010 Apr;59(4):609-18. doi: 10.1007/s00262-009-0788-2. Epub 2009 Nov 6. Cancer Immunol Immunother. 2010. PMID: 19894047 Free PMC article.

5

T cell assays and MIATA: the essential minimum for maximum impact.

Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff TH, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM. Britten CM, et al. Among authors: janetzki s. Immunity. 2012 Jul 27;37(1):1-2. doi: 10.1016/j.immuni.2012.07.010. Immunity. 2012. PMID: 22840835 Free article. No abstract available.

6

Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium.

Britten CM, Janetzki S, Ben-Porat L, Clay TM, Kalos M, Maecker H, Odunsi K, Pride M, Old L, Hoos A, Romero P; HLA-peptide Multimer Proficiency Panel of the CVC-CRI Immune Assay Working Group. Britten CM, et al. Among authors: janetzki s. Cancer Immunol Immunother. 2009 Oct;58(10):1701-13. doi: 10.1007/s00262-009-0681-z. Epub 2009 Mar 4. Cancer Immunol Immunother. 2009. PMID: 19259668 Free PMC article.

7

The impact of harmonization on ELISPOT assay performance.

Janetzki S, Britten CM. Janetzki S, et al. Methods Mol Biol. 2012;792:25-36. doi: 10.1007/978-1-61779-325-7_2. Methods Mol Biol. 2012. PMID: 21956498

8

Enzyme-Linked ImmunoSpot (ELISpot) for Single-Cell Analysis.

Janetzki S, Rabin R. Janetzki S, et al. Methods Mol Biol. 2015;1346:27-46. doi: 10.1007/978-1-4939-2987-0_3. Methods Mol Biol. 2015. PMID: 26542713

9

Insect cells as HLA-restricted antigen-presenting cells for the IFN-gamma elispot assay.

Janetzki S, Song P, Gupta V, Lewis JJ, Houghton AN. Janetzki S, et al. J Immunol Methods. 2000 Feb 3;234(1-2):1-12. doi: 10.1016/s0022-1759(99)00203-3. J Immunol Methods. 2000. PMID: 10669764

10

Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide.

Lewis JJ, Janetzki S, Schaed S, Panageas KS, Wang S, Williams L, Meyers M, Butterworth L, Livingston PO, Chapman PB, Houghton AN. Lewis JJ, et al. Among authors: janetzki s. Int J Cancer. 2000 Aug 1;87(3):391-8. doi: 10.1002/1097-0215(20000801)87:3<391::aid-ijc13>3.0.co;2-k. Int J Cancer. 2000. PMID: 10897045 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

59 results

Search Page

Filters